The 36-month beta value for TNXP is at 2.19. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TNXP is 95.54M, and currently, shorts hold a 1.67% of that float. The average trading volume for TNXP on May 20, 2024 was 2.44M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
TNXP) stock’s latest price update
The stock of Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) has increased by 8.59 when compared to last closing price of 0.18.Despite this, the company has seen a gain of 14.85% in its stock price over the last five trading days. globenewswire.com reported 2024-05-15 that CHATHAM, N.J., May 15, 2024 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Seth Lederman, M.D., Chief Executive Officer, will participate virtually in a fireside chat at A.G.P.’s Healthcare Company Showcase on Tuesday, May 21, 2024, at 9:00 a.m. ET.
TNXP’s Market Performance
TNXP’s stock has risen by 14.85% in the past week, with a monthly rise of 25.61% and a quarterly drop of -48.31%. The volatility ratio for the week is 5.84% while the volatility levels for the last 30 days are 7.25% for Tonix Pharmaceuticals Holding Corp The simple moving average for the last 20 days is 13.15% for TNXP’s stock, with a simple moving average of -58.93% for the last 200 days.
Analysts’ Opinion of TNXP
ROTH Capital, on the other hand, stated in their research note that they expect to see TNXP reach a price target of $4. The rating they have provided for TNXP stocks is “Buy” according to the report published on April 18th, 2019.
ROTH Capital gave a rating of “Buy” to TNXP, setting the target price at $6 in the report published on August 18th of the previous year.
TNXP Trading at -12.33% from the 50-Day Moving Average
After a stumble in the market that brought TNXP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.72% of loss for the given period.
Volatility was left at 7.25%, however, over the last 30 days, the volatility rate increased by 5.84%, as shares surge +23.25% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -47.16% lower at present.
During the last 5 trading sessions, TNXP rose by +14.85%, which changed the moving average for the period of 200-days by -80.48% in comparison to the 20-day moving average, which settled at $0.1761. In addition, Tonix Pharmaceuticals Holding Corp saw -51.07% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for TNXP
Current profitability levels for the company are sitting at:
- -10.32 for the present operating margin
- -2.6 for the gross margin
The net margin for Tonix Pharmaceuticals Holding Corp stands at -9.62. The total capital return value is set at -0.92. Equity return is now at value -72.08, with -62.71 for asset returns.
Based on Tonix Pharmaceuticals Holding Corp (TNXP), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -9.29. The debt to equity ratio resting at 0.09. The interest coverage ratio of the stock is -59.12.
Currently, EBITDA for the company is -114.09 million with net debt to EBITDA at -0.03. When we switch over and look at the enterprise to sales, we see a ratio of 2.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.47.
Conclusion
In conclusion, Tonix Pharmaceuticals Holding Corp (TNXP) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
